Results 211 to 220 of about 13,806,711 (306)

Reflections and lessons learned from implementing the Ontario Health Equity Impact Assessment Tool in community practice. [PDF]

Public Health Pract (Oxf)
Routledge F, Campanella S, Lunsky Y, Lake J, Po-Lun Fung K.   +4 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Updating the global weighting factor for biodiversity impact assessment in LCA. [PDF]

Data Brief
Quandt J, Lindner JP, Mumm N, von Hippel B.   +3 more
europepmc   +1 more source

Let’s Be Clear—Health Impact Assessments or Assessing Health Impacts?

Public Health Reviews
Jinhee Kim, Andrew Dannenberg, Andrew Dannenberg, Fiona Haigh, Fiona Haigh, Ben Harris-Roxas, Ben Harris-Roxas   +6 more
openaire   +4 more sources

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Review on Predictive Models and Integration Strategies for Holistic Impact Assessment of Chemicals and Materials. [PDF]

Environ Sci Technol
Serra A, Torres Maia M, Tsiros P, Minadakis V, Riudavets-Puig R, Perello-Y-Bestard A, Nikiforou F, Karakoltzidis A, Di Lieto E, Schaffert A, Al-Abdulraheem Z, Virmani I, Dziubaniuk O, Karhukorpi S, Dokler J, Zouraris D, Mintis DG, Varsou DD, Tsoumanis A, Melagraki G, Isigonis P, Papadiamantis AG, Buljan M, Agalliadou A, Ellis LA, Sergent JA, Alves Siqueira de Assunção M, Martinez DST, Winkler D, Park SG, Ha SM, Gerelkhuu Z, Yoon TH, Karakitsios S, Sarigiannis DA, Afantitis A, Cucurachi S, Serchi T, Marvuglia A, Exner T, Siltaloppi J, Paparella M, Peijnenburg W, Wick P, Lynch I, Sarimveis H, Greco D.   +46 more
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Understanding LUng Cancer risk factors and their Impact Assessment (LUCIA): protocol for multicentre observational cohort study. [PDF]

BMJ Open
Idoyaga-Uribarrena JE, García-Echeberria L, Lecumberri I, Azkona E, Jiménez U, Sainz-Camín M, Núñez-Benjumea FJ, Luque-Romero LG, Ernst B, Guiot J, Stonāns I, Krams A, Macia I, Garin-Muga A, Gut IG, Gut M, Orcajo-Lago J, Arana-Arri E, LUCIA Study Group members. TECHNION - Israel Institute of Technology (TECH-Israel).   +18 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

The burden and risk factors of NCDs in Zimbabwe: evidence from the Zimbabwe population based HIV impact assessment 2020 survey. [PDF]

BMC Public Health
Mapingure MP, Dzinamarira T, Chingombe I, Moyo E, Mpofu A, Mugurungi O, Herrera H, Madziva R, Musuka GN.   +8 more
europepmc   +1 more source